Genentech denies US specialists of Avastin

Genentech is seeking to restrict the use of its anti-VEGF drug Avastin by ophthalmologists in the US.

Genentech is seeking to restrict the use of its anti-VEGF drug Avastin by ophthalmologists in the US.

Avastin is currently approved as an anti-cancer treatment, however, ophthalmologists have been using the agent off-label for the treatment of age-related macular degeneration (AMD).

The move is not proving popular with some doctors, who say it may force them to use Genentech's much more expensive drug, Lucentis. Lucentis costs approximately $2,000 a dose, while Avastin costs just $50 a dose.

In a letter to retina specialists, Genentech said that, as of November 30, 2007, its wholesalers would no longer provide Avastin to compounding pharmacies — companies that can divide a vial of Avastin into smaller portions for use in the eye.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Related Content
© 2023 MJH Life Sciences

All rights reserved.